Validity and Reliability of Commercially Available Bioelectrical Impedance Analysis Devices
NCT ID: NCT05026697
Last Updated: 2022-08-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
75 participants
OBSERVATIONAL
2021-06-09
2021-12-10
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Development of a Segmental Bioelectrical Impedance Spectroscopy Device for Body Composition Measurement
NCT04006899
InBody Validation Study
NCT02635958
Multi-frequency Bioelectrical Impedance for Estimating Total Body Water by Deuterium Dilution
NCT01607229
Tanita BIA System Validation
NCT02118675
Comparison of Bioimpedance Body Composition Device Measurements
NCT01888068
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This study will involve 1-2 total visits: one initial visit followed by an optional follow-up visit 12-16 weeks later. These visits will consist of body composition assessments after an overnight fast. Before the overnight fast, the individual will be asked to drink 1 liter (the equivalent of two 16.9-ounce water bottles) between the final meal of the day and the beginning of the 8-hour fasting period. At the first visit, participants will undergo dual x-ray absorptiometry (DXA; GE Lunar Prodigy), air displacement plethysmography (ADP; Cosmed Bod Pod), a 3D body scan (SizeStream SS20), and several multi- and single-frequency bioelectrical impedance analysis (BIA) assessments. The BIA assessment methods will be conducted twice. This will allow for test-retest reliability assessment of each of the BIA devices being assessed in our study. At the optional second visit, all assessment methods utilized in our laboratory will be conducted once. By comparing these values to the values from the first visit, we will be able to establish the cumulative error due to technical error and biological error (i.e. random biological differences in the participants between the two assessments). We will collect data in a similar fashion during this second visit in order to compare the changes over time between the measurements provided by the commercially available BIA devices against the changes detected by a validated 4-compartment model of body composition, which uses research-grade devices. Cumulatively, this information will provide essential data to consumers regarding both the immediate and long-term test-retest reliability as well as the validity of commercially available BIA devices such as home body fat scales.
The commercially available BIA devices being examined in the present study includes:
* Omron HBF-306
* RENPHO Smart Bathroom Scale (item number: ES-26BB-B)
* Hawanna Body Fat Scale (UPC: 791555289926)
* Wyze Scale (SKU: WHSCL1)
* INEVIFIT Smart Body Fat Scale (UPC: 711841680565; EAN: 0711841680565)
* WeightWatchers Scale by Conair (model: WW721XF)
* Tanita UM-081 (model: UM-081; EAN: 0742496801012 and 0885157966993)
* VitaGoods FormFit Digital Scale and Body Analyzer (model: VG42252-0000)
* Omron HBF 516 Body Composition Monitor (model: HBF-516B)
* Seca sensa 804
* Withings/Nokia BodyCardio Body Composition Digital Scale (model: WBS04b-Black-All-Inter)
* Tanita BC554 IronMan Body Composition Monitor (model: BC-554)
* Tanita BC568 InnerScan Segmental Body Composition Monitor (model: BC-568)
* InBody H2ON Smart Full Body Composition Analyzer
Additionally, several laboratory-grade bioimpedance technologies will be performed, including ImpediMed SFB7 bioimpedance spectroscopy and Seca mBCA 515/514 multi-frequency bioelectrical impedance analysis. Urine specific gravity will also be assessed using digital refractometry, and height will be assessed via stadiometer. As part of the ADP test, body mass estimates from a calibrated, research-grade scale will be obtained (Modified BWB-627-A, Tanita Corporation).
The test-retest reliability of the commercially available bioelectrical impedance analysis devices will be examined through duplicate assessments. The validity of the commercially available bioelectrical impedance analysis devices will be examined as compared to the criterion laboratory methods, namely the 4-compartment model for total body composition and DXA and/or laboratory-grade segmental bioimpedance technologies for segmental body composition.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Generally healthy (defined as an absence of any disease or medical condition which could potentially result in abnormal body composition, including but not limited to musculoskeletal or metabolic diseases)
* Weight-stable (defined as no change in body mass \>5 pounds in the past month)
* Height greater than 75.5 inches (due to height limitation of DXA scanner)
* Weight greater than 330 pounds (due to weight limitation of some of the devices used)
* Presence of facial hair longer than 1/2 inch (and unwillingness to shave) or self-report of large amounts of body hair due to the impact of hair on Bod Pod body volume estimates
* Presence of pacemaker or any electrical device (due to electrical currents administered by bioimpedance devices)
* Amputation of limb, implantation of a meaningful amount metal (e.g., full joint replacement), or physical deformity large enough to invalidate traditional body composition assessments
18 Years
50 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Texas Tech University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Grant Tinsley, PhD
Role: PRINCIPAL_INVESTIGATOR
Texas Tech University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Kinesiology & Sport Management
Lubbock, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IRB2021-107
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.